<DOC>
	<DOCNO>NCT00965718</DOCNO>
	<brief_summary>Phase 2 Clinical trial Evaluate efficacy safety activate T-lymphocyte ( `` Immuncell-LC '' ) cell therapy Gemcitabine refractory advance pancreatic cancer</brief_summary>
	<brief_title>Evaluate Efficacy Safety Activated T-lymphocyte Cell Therapy Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This design single-center , single group clinical trial , subject include patient pathologically-confirmed Gemcitabine refractory advance pancreatic cancer . If subject agree participate clinical trial sign write consent , appropriate subject , meet criterion examination test , undergo clinical trial . To participate clinical trial , subject 's blood 60 ml withdrawn make study drug least 2 week administration . Subjects visit hospital accord protocol receive study drug . Therapeutic response rate , overall survival rate , time progression quality life investigate .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Subject sign write consent form , protector legal representative prior clinical trial person charge explain fully objective , procedure characteristic study drug . 2 . Patient age 18 75 3 . Patient pathologicallyconfirmed , advance pancreatic cancer 4 . ECOG scale ( ECOGPS ) â‰¤2 ( Appendix 4 . Performance status scale/score ) 5 . Patient anticipate survival period 3 month 6 . Patient progress disease Gemcitabinebased primary anticancer chemotherapy 7 . Patient whose blood test , renal function test liver function test result meet following condition . 1 . Patient medical history immunodeficiency autoimmune disease could aggravate immunotherapy ( example : rheumatoid arthritis , systemic lupus erythematosus , vasculitis , multiple sclerosis , adolescent InsulinDependent Diabetes Mellitus , etc . ) 2 . Confirmed immunodeficient patient 3 . Patient history cancer skin cancer , local prostate cancer carcinoma situ cervix within last 5 year start study 4 . Patient receive systemic antiangiogenic agent 5 . Patient receive chemotherapy Gemcitabine base chemotherapy 6 . Obvious myocardial failure uncontrolled arterial hypertension 7 . Patient experience serious allergy ( judged investigator ) 8 . Patient serious psychological disease ( judged investigator ) 9 . Pregnant woman , breastfeed woman woman want pregnant trial period 10 . Patient participate another clinical trial within last 4 week start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
</DOC>